625 related articles for article (PubMed ID: 29650132)
41. [Is down-staging of advanced bladder cancer by neoadjuvant chemotherapy possible?--MVEC protocol].
Hoch V; Noll F; Schreiter F
Urologe A; 1992 Jul; 31(4):243-6. PubMed ID: 1514212
[TBL] [Abstract][Full Text] [Related]
42. The effect of concomitant carcinoma in situ on neoadjuvant chemotherapy for urothelial cell carcinoma of the bladder: inferior pathological outcomes but no effect on survival.
Parker WP; Ho PL; Melquist JJ; Scott K; Holzbeierlein JM; Lopez-Corona E; Kamat AM; Lee EK
J Urol; 2015 May; 193(5):1494-9. PubMed ID: 25451834
[TBL] [Abstract][Full Text] [Related]
43. Adjuvant and neoadjuvant chemotherapy for urothelial carcinoma.
McCaffrey JA; Herr HW
Surg Oncol Clin N Am; 1997 Oct; 6(4):667-81. PubMed ID: 9309087
[TBL] [Abstract][Full Text] [Related]
44. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
[TBL] [Abstract][Full Text] [Related]
45. [Systemic therapy of muscle invasive bladder cancer - an update].
Niedersüss-Beke D
Wien Med Wochenschr; 2011 Aug; 161(15-16):371-3. PubMed ID: 21953426
[TBL] [Abstract][Full Text] [Related]
46. Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer.
Raj GV; Karavadia S; Schlomer B; Arriaga Y; Lotan Y; Sagalowsky A; Frenkel E
Cancer; 2011 Jan; 117(2):276-82. PubMed ID: 20830767
[TBL] [Abstract][Full Text] [Related]
47. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer.
Porter MP; Kerrigan MC; Donato BM; Ramsey SD
Urol Oncol; 2011; 29(3):252-8. PubMed ID: 19450992
[TBL] [Abstract][Full Text] [Related]
48. Radiation, chemotherapy and transurethral surgery: an organ-sparing alternative to the radical cystectomy.
Zietman AL
Front Radiat Ther Oncol; 2002; 36():131-46. PubMed ID: 11842743
[No Abstract] [Full Text] [Related]
49. Current status of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.
Rosenberg JE
Expert Rev Anticancer Ther; 2007 Dec; 7(12):1729-36. PubMed ID: 18062747
[TBL] [Abstract][Full Text] [Related]
50. Impact of adjuvant chemotherapy in patients with upper tract urothelial carcinoma and lymphovascular invasion after radical nephroureterectomy.
Lee KS; Kim KH; Yoon YE; Choi KH; Yang SC; Han WK
Korean J Urol; 2015 Jan; 56(1):41-7. PubMed ID: 25598935
[TBL] [Abstract][Full Text] [Related]
51. Investigation of eligibility for adjuvant therapy from real-world data of patients with urothelial carcinoma undergoing radical cystectomy and radical nephroureterectomy.
Matsue T; Kato M; Kosugi Y; Ishizaki K; Masuda H; Yamamoto S; Takeyama Y; Yukimatsu N; Otoshi T; Yamasaki T; Kuratsukuri K; Uchida J
Jpn J Clin Oncol; 2024 Feb; 54(2):182-191. PubMed ID: 37967156
[TBL] [Abstract][Full Text] [Related]
52. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy.
Aparicio AM; Elkhouiery AB; Quinn DI
Urol Clin North Am; 2005 May; 32(2):217-30, vii. PubMed ID: 15862619
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium.
Shariat SF; Karakiewicz PI; Palapattu GS; Lotan Y; Rogers CG; Amiel GE; Vazina A; Gupta A; Bastian PJ; Sagalowsky AI; Schoenberg MP; Lerner SP
J Urol; 2006 Dec; 176(6 Pt 1):2414-22; discussion 2422. PubMed ID: 17085118
[TBL] [Abstract][Full Text] [Related]
54. Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma.
Soga N; Arima K; Sugimura Y
Int J Urol; 2008 Sep; 15(9):800-3. PubMed ID: 18651862
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy.
Leow JJ; Chong YL; Chang SL; Valderrama BP; Powles T; Bellmunt J
Eur Urol; 2021 May; 79(5):635-654. PubMed ID: 32798146
[TBL] [Abstract][Full Text] [Related]
56. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
57. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy.
Rajput MZ; Kamat AM; Clavell-Hernandez J; Siefker-Radtke AO; Grossman HB; Dinney CP; Matin SF
Urology; 2011 Jul; 78(1):61-7. PubMed ID: 21354598
[TBL] [Abstract][Full Text] [Related]
58. Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial.
Birtle AJ; Jones R; Chester J; Lewis R; Biscombe K; Johnson M; Blacker A; Bryan RT; Catto JWF; Choudhury A; Das P; Jagdev S; Powles T; Wagstaff J; Cheung KC; Cafferty F; Hall E
J Clin Oncol; 2024 May; 42(13):1466-1471. PubMed ID: 38350047
[No Abstract] [Full Text] [Related]
59. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
[TBL] [Abstract][Full Text] [Related]
60. [ypT0N0 after neoadjuvant chemotherapy and cystectomy for muscle-invasive bladder cancer: Incidence and prognosis. A review from the Bladder group of the French Committee of Oncology].
Pignot G; Houédé N; Roumiguié M; Audenet F; Brunelle S; Colin P; Compérat E; Larré S; Masson-Lecomte A; Neuzillet Y; Xylinas E; Méjean A; Rouprêt M;
Prog Urol; 2018 Oct; 28(12):567-574. PubMed ID: 30205925
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
